What’s Driving the Boom in Early Stage Biotech Funding?
The LabTech website noted that J&J Innovation is one of the many investors that are turning their gaze to the promise of early-stage research. J&J Innovation is following a strategy focusing on supporting ‘open innovation’, an approach that they believe could work where the traditional pharma approach has failed. J&J entered a collaboration
Comments Off on What’s Driving the Boom in Early Stage Biotech Funding? • Read this story »
More Articles
Drug Consortium Offers $50M for Collective Research
MarketWatch website reports that the Takeda Pharmaceutical Company has joined the Structural Genomics Consortium (SGC) to fund collective drug research aimed at bringing new, more effective medicines to market faster. Takeda’s contribution raises the total to $50 million in support of the SGC